Lumateperone

證據等級: L5

預測適應症: 9 個

Lumateperone: Original Indication Not Documented → Predicted Signal for Retinal Dystrophy with or without Extraocular Anomalies

One-Sentence Summary

Lumateperone’s original indication and mechanism of action are not available in this Evidence Pack (both flagged as data gaps, one of them Blocking). The TxGNN model predicts a possible link to retinal dystrophy with or without extraocular anomalies, but this is supported by 0 clinical trials and 15 publications that do not mention lumateperone at all — the evidence pack’s own mechanistic assessment concludes there is no known or plausible biological link between the drug and this disease.

Quick Overview

Item	Content
Original Indication	Not available — no licenses or indication text in this Evidence Pack (Data Gap, drug’s original use is not documented)
Predicted New Indication	Retinal dystrophy with or without extraocular anomalies
TxGNN Prediction Score	99.97% (rank 1345 among all predictions)
Evidence Level	L5 (model prediction only, no supporting studies)
US Market Status	Not Marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for lumateperone in this Evidence Pack (DG002, High severity). Based on the repurposing rationale supplied alongside the prediction, lumateperone is understood to act as a modulator of 5-HT2A, D1, and D2 receptors and an inhibitor of the serotonin transporter (SERT) — a centrally-acting neurotransmission-modulating profile typically associated with psychiatric indications.

Retinal dystrophy with or without extraocular anomalies, however, is a congenital/structural developmental eye disorder, not a disease driven by neurotransmitter imbalance. The Evidence Pack’s own mechanistic assessment is explicit on this point: there is no known or biologically plausible connection between lumateperone’s receptor-modulation mechanism and this disease. The very high TxGNN score (99.97%) is not corroborated by any clinical, literature, or mechanistic support — it should be treated as a raw model output rather than a validated signal.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

The 15 publications returned by the search co-mention the drug and disease terms but, on review of their abstracts, are general ophthalmology/orbital-disease reviews and case reports — none discuss lumateperone specifically. They are listed here for transparency, not as evidence of drug efficacy.

PMID	Year	Type	Journal	Key Findings
9416661	1997	Review	Semin Ultrasound CT MR	General review of orbital infections; no mention of lumateperone or retinal dystrophy treatment
20127583	2010	Review	Semin Neurol	Clinical approach to diplopia; unrelated to the drug
38321238	2024	Review	Pediatr Radiol	Imaging review of pediatric ocular pathologies including congenital retinal/vitreous conditions
38249493	2023	Review	Taiwan J Ophthalmol	Congenital anomalies of lens shape; developmental eye disorder background only
22241537	2012	Review	Klin Monbl Augenheilkd	Congenital ptosis review; unrelated to the drug
109006	1979	Case Report	Am J Ophthalmol	Case report of unilateral cryptophthalmia; unrelated to the drug
7035111	1981	Review	Doc Ophthalmol	Wagner-Stickler syndrome vitreoretinal degeneration review
33806565	2021	Review	Int J Mol Sci	Retinal abnormalities in congenital fibrosis of extraocular muscles (genetic disorder)
30196776	2018	Review	J Binocul Vis Ocul Motil	Congenital cranial dysinnervation disorders review
24932988	2014	Review	Am J Ophthalmol	Pathogenesis/treatment of maculopathy with cavitary optic disc anomalies

US Market Information

No market authorization records are available. market_status is recorded as “Not Marketed” with 0 licenses on file.

Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and drug-interaction data are all flagged as data gaps in this Evidence Pack; DG001 — TFDA label warnings/contraindications — is rated Blocking severity, meaning it must be resolved before any safety pre-assessment can proceed.)

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction sits at Evidence Level L5 — a model score with no supporting clinical trials, no relevant literature, and no plausible mechanistic link (the drug’s presumed neurotransmitter-modulating mechanism does not align with a congenital structural eye disorder). This same pattern (very high TxGNN score, zero trials/literature, Hold recommendation) also holds for all other ranked candidates for this drug (ranks 2–9: polymicrogyria/cerebellar hypoplasia, hydranencephaly, CMT1G, X-linked myopia variants, glycosylation disorder, atypical glycine encephalopathy), suggesting the model is not currently producing a differentiated, actionable repurposing signal for lumateperone.

To proceed, the following is needed:

Original indication and mechanism of action data for lumateperone (currently undocumented in this pack)
TFDA label warnings/contraindications (DG001, Blocking — required before any safety pre-assessment)
Drug-specific clinical or preclinical evidence connecting lumateperone to retinal dystrophy or any other candidate indication before advancing past S0
Reassessment of whether this drug/indication pair merits continued monitoring, given the absence of a plausible mechanistic hypothesis
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.